Clinical trials: Optimization of Laboratory Procedures
Copy Number Variations
Development of a NIPTT for Detecting Copy Number Variations
To collect whole blood samples from pregnant women for the purpose of developing, optimizing and evaluating laboratory-developed noninvasive prenatal test (NIPT) for the detection of fetal chromosomal abnormalities of interest…
- Trial name
- NCT04774640
- Testing
- MaterniT GENOME
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sequenom, Inc.
Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or…
- Trial name
- NCT07070232
- Testing
- BNT326, Pumitamig, Itraconazole
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 1,438 people
- Sponsor
- BioNTech SE
Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a multi-site, open-label, dose-finding study, consisting of Parts 1, 2a, and 2b to investigate the combination of BNT326 with pumitamig (also known as BNT327 or PM8002) in participants with relapsed, progressive as well…
- Trial name
- NCT07111520
- Testing
- BNT326, Pumitamig
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 880 people
- Sponsor
- BioNTech SE
Healthy
A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the Body
The main objective of this trial is to select a formulation and to optimize the identified formulation of BI 685509, if needed.
- Trial name
- NCT04926246
- Testing
- R1: Reference Product X, T1: Test Product M, T2: Test Product N
- Where
- United Kingdom
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study in Healthy Men to Find the Best Formulation of BI 894416 and to Test How This is Taken up in the Body
The main objective of this trial is to select a formulation principle (tablet vs. capsule) and to optimize the identified extended release formulation of BI 894416, if needed.
- Trial name
- NCT04232839
- Testing
- BI 894416 Reference Formulation, BI 894416 Formulation A2, BI 894416 Formulation C2
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer…
- Trial name
- NCT07079631
- Testing
- BNT314, Pumitamig, SoC chemotherapy treatment 1
- Where
- 14 sites in United States, Germany and 3 more
- Volunteers
- 482 people
- Sponsor
- BioNTech SE
Healthy
Non-invasive Sampling Method for Skin Test: Optimization of Sample Collection and Extraction
When absorbent hygiene products-such as panty liners, sanitary pads, incontinence products, or wound care items-are used over extended periods, they can sometimes have negative effects on the skin.
- Trial name
- SPECIMEN (NCT07117747)
- Testing
- Healthy volunteers
- Where
- Sweden
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Essity Hygiene and Health AB
Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery.
- Conditions
- Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06324357
- Testing
- Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine
- Where
- 104 sites in United States, Belgium and 8 more
- Volunteers
- 910 people
- Sponsor
- Boehringer Ingelheim